Request Free Sample ×
Muscle Wasting Disorders Market Research Report-Global Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Muscle Wasting Disorders Market

ID: MRFR/HC/21141-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026

Muscle Wasting Disorders Market Research Report By Disease Type (Muscular Dystrophy, Spinal Muscular Atrophy, Amyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis, Other Muscle Wasting Disorders), By Treatment Modality (Drug Therapies, Gene Therapy, Physical Therapy and Rehabilitation, Supplements and Nutrition, Other Treatment Modalities), By Mechanism of Action (Anti-inflammatory Agents, Muscle Growth Stimulators, Gene Editing Therapies, Immunomodulators, Other Mechanisms of Action), By Route of Administration (Oral, Intravenous, Intramuscular, Transdermal, Other Routes of Administration) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Muscle Wasting Disorders Market Infographic
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Disease Type (USD Billion)
      1. 4.1.1 Muscular Dystrophy
      2. 4.1.2 Spinal Muscular Atrophy
      3. 4.1.3 Amyotrophic Lateral Sclerosis (ALS)
      4. 4.1.4 Myasthenia Gravis
      5. 4.1.5 Other Muscle Wasting Disorders
    2. 4.2 Healthcare, BY Treatment Modality (USD Billion)
      1. 4.2.1 Drug Therapies
      2. 4.2.2 Gene Therapy
      3. 4.2.3 Physical Therapy and Rehabilitation
      4. 4.2.4 Supplements and Nutrition
      5. 4.2.5 Other Treatment Modalities
    3. 4.3 Healthcare, BY Mechanism of Action (USD Billion)
      1. 4.3.1 Anti-inflammatory Agents
      2. 4.3.2 Muscle Growth Stimulators
      3. 4.3.3 Gene Editing Therapies
      4. 4.3.4 Immunomodulators
      5. 4.3.5 Other Mechanisms of Action
    4. 4.4 Healthcare, BY Route of Administration (USD Billion)
      1. 4.4.1 Oral
      2. 4.4.2 Intravenous
      3. 4.4.3 Intramuscular
      4. 4.4.4 Transdermal
      5. 4.4.5 Other Routes of Administration
    5. 4.5 Healthcare, BY Region (USD Billion)
      1. 4.5.1 North America
        1. 4.5.1.1 US
        2. 4.5.1.2 Canada
      2. 4.5.2 Europe
        1. 4.5.2.1 Germany
        2. 4.5.2.2 UK
        3. 4.5.2.3 France
        4. 4.5.2.4 Russia
        5. 4.5.2.5 Italy
        6. 4.5.2.6 Spain
        7. 4.5.2.7 Rest of Europe
      3. 4.5.3 APAC
        1. 4.5.3.1 China
        2. 4.5.3.2 India
        3. 4.5.3.3 Japan
        4. 4.5.3.4 South Korea
        5. 4.5.3.5 Malaysia
        6. 4.5.3.6 Thailand
        7. 4.5.3.7 Indonesia
        8. 4.5.3.8 Rest of APAC
      4. 4.5.4 South America
        1. 4.5.4.1 Brazil
        2. 4.5.4.2 Mexico
        3. 4.5.4.3 Argentina
        4. 4.5.4.4 Rest of South America
      5. 4.5.5 MEA
        1. 4.5.5.1 GCC Countries
        2. 4.5.5.2 South Africa
        3. 4.5.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Roche (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Bristol-Myers Squibb (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Pfizer (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Eli Lilly (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Amgen (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sanofi (FR)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 AstraZeneca (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Merck & Co. (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY DISEASE TYPE
    4. 6.4 US MARKET ANALYSIS BY TREATMENT MODALITY
    5. 6.5 US MARKET ANALYSIS BY MECHANISM OF ACTION
    6. 6.6 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    7. 6.7 CANADA MARKET ANALYSIS BY DISEASE TYPE
    8. 6.8 CANADA MARKET ANALYSIS BY TREATMENT MODALITY
    9. 6.9 CANADA MARKET ANALYSIS BY MECHANISM OF ACTION
    10. 6.10 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    11. 6.11 EUROPE MARKET ANALYSIS
    12. 6.12 GERMANY MARKET ANALYSIS BY DISEASE TYPE
    13. 6.13 GERMANY MARKET ANALYSIS BY TREATMENT MODALITY
    14. 6.14 GERMANY MARKET ANALYSIS BY MECHANISM OF ACTION
    15. 6.15 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    16. 6.16 UK MARKET ANALYSIS BY DISEASE TYPE
    17. 6.17 UK MARKET ANALYSIS BY TREATMENT MODALITY
    18. 6.18 UK MARKET ANALYSIS BY MECHANISM OF ACTION
    19. 6.19 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    20. 6.20 FRANCE MARKET ANALYSIS BY DISEASE TYPE
    21. 6.21 FRANCE MARKET ANALYSIS BY TREATMENT MODALITY
    22. 6.22 FRANCE MARKET ANALYSIS BY MECHANISM OF ACTION
    23. 6.23 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    24. 6.24 RUSSIA MARKET ANALYSIS BY DISEASE TYPE
    25. 6.25 RUSSIA MARKET ANALYSIS BY TREATMENT MODALITY
    26. 6.26 RUSSIA MARKET ANALYSIS BY MECHANISM OF ACTION
    27. 6.27 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    28. 6.28 ITALY MARKET ANALYSIS BY DISEASE TYPE
    29. 6.29 ITALY MARKET ANALYSIS BY TREATMENT MODALITY
    30. 6.30 ITALY MARKET ANALYSIS BY MECHANISM OF ACTION
    31. 6.31 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    32. 6.32 SPAIN MARKET ANALYSIS BY DISEASE TYPE
    33. 6.33 SPAIN MARKET ANALYSIS BY TREATMENT MODALITY
    34. 6.34 SPAIN MARKET ANALYSIS BY MECHANISM OF ACTION
    35. 6.35 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    36. 6.36 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE
    37. 6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT MODALITY
    38. 6.38 REST OF EUROPE MARKET ANALYSIS BY MECHANISM OF ACTION
    39. 6.39 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    40. 6.40 APAC MARKET ANALYSIS
    41. 6.41 CHINA MARKET ANALYSIS BY DISEASE TYPE
    42. 6.42 CHINA MARKET ANALYSIS BY TREATMENT MODALITY
    43. 6.43 CHINA MARKET ANALYSIS BY MECHANISM OF ACTION
    44. 6.44 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    45. 6.45 INDIA MARKET ANALYSIS BY DISEASE TYPE
    46. 6.46 INDIA MARKET ANALYSIS BY TREATMENT MODALITY
    47. 6.47 INDIA MARKET ANALYSIS BY MECHANISM OF ACTION
    48. 6.48 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    49. 6.49 JAPAN MARKET ANALYSIS BY DISEASE TYPE
    50. 6.50 JAPAN MARKET ANALYSIS BY TREATMENT MODALITY
    51. 6.51 JAPAN MARKET ANALYSIS BY MECHANISM OF ACTION
    52. 6.52 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    53. 6.53 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE
    54. 6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT MODALITY
    55. 6.55 SOUTH KOREA MARKET ANALYSIS BY MECHANISM OF ACTION
    56. 6.56 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    57. 6.57 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE
    58. 6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT MODALITY
    59. 6.59 MALAYSIA MARKET ANALYSIS BY MECHANISM OF ACTION
    60. 6.60 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    61. 6.61 THAILAND MARKET ANALYSIS BY DISEASE TYPE
    62. 6.62 THAILAND MARKET ANALYSIS BY TREATMENT MODALITY
    63. 6.63 THAILAND MARKET ANALYSIS BY MECHANISM OF ACTION
    64. 6.64 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    65. 6.65 INDONESIA MARKET ANALYSIS BY DISEASE TYPE
    66. 6.66 INDONESIA MARKET ANALYSIS BY TREATMENT MODALITY
    67. 6.67 INDONESIA MARKET ANALYSIS BY MECHANISM OF ACTION
    68. 6.68 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    69. 6.69 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE
    70. 6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT MODALITY
    71. 6.71 REST OF APAC MARKET ANALYSIS BY MECHANISM OF ACTION
    72. 6.72 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    73. 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. 6.74 BRAZIL MARKET ANALYSIS BY DISEASE TYPE
    75. 6.75 BRAZIL MARKET ANALYSIS BY TREATMENT MODALITY
    76. 6.76 BRAZIL MARKET ANALYSIS BY MECHANISM OF ACTION
    77. 6.77 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    78. 6.78 MEXICO MARKET ANALYSIS BY DISEASE TYPE
    79. 6.79 MEXICO MARKET ANALYSIS BY TREATMENT MODALITY
    80. 6.80 MEXICO MARKET ANALYSIS BY MECHANISM OF ACTION
    81. 6.81 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    82. 6.82 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE
    83. 6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT MODALITY
    84. 6.84 ARGENTINA MARKET ANALYSIS BY MECHANISM OF ACTION
    85. 6.85 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE
    87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT MODALITY
    88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY MECHANISM OF ACTION
    89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    90. 6.90 MEA MARKET ANALYSIS
    91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE
    92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT MODALITY
    93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY MECHANISM OF ACTION
    94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE
    96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT MODALITY
    97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY MECHANISM OF ACTION
    98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    99. 6.99 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE
    100. 6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT MODALITY
    101. 6.101 REST OF MEA MARKET ANALYSIS BY MECHANISM OF ACTION
    102. 6.102 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. 6.104 RESEARCH PROCESS OF MRFR
    105. 6.105 DRO ANALYSIS OF HEALTHCARE
    106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. 6.109 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE)
    110. 6.110 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion)
    111. 6.111 HEALTHCARE, BY TREATMENT MODALITY, 2024 (% SHARE)
    112. 6.112 HEALTHCARE, BY TREATMENT MODALITY, 2024 TO 2035 (USD Billion)
    113. 6.113 HEALTHCARE, BY MECHANISM OF ACTION, 2024 (% SHARE)
    114. 6.114 HEALTHCARE, BY MECHANISM OF ACTION, 2024 TO 2035 (USD Billion)
    115. 6.115 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    116. 6.116 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.2.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.3.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.3.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.3.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.4.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.4.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.4.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.5.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.5.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.5.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.6.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.6.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.6.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.7.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.7.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.7.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.8.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.8.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.8.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.9.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.9.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.9.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.10.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.10.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.10.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.11.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.11.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.11.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.12.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.12.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.12.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.13.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.13.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.13.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.14.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.14.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.14.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.15.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.15.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.15.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.16.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.16.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.16.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.17.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.17.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.17.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.18.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.18.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.18.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.19.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.19.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.19.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.20.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.20.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.20.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.21.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.21.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.21.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.22.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.22.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.22.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.23.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.23.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.23.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.24.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.24.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.24.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.25.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.25.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.25.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.26.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.26.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.26.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.27.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.27.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.27.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.28.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.28.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.28.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.29.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.29.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.29.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.30.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
      3. 7.30.3 BY MECHANISM OF ACTION, 2025-2035 (USD Billion)
      4. 7.30.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Healthcare Market Segmentation

Healthcare By Disease Type (USD Billion, 2025-2035)

  • Muscular Dystrophy
  • Spinal Muscular Atrophy
  • Amyotrophic Lateral Sclerosis (ALS)
  • Myasthenia Gravis
  • Other Muscle Wasting Disorders

Healthcare By Treatment Modality (USD Billion, 2025-2035)

  • Drug Therapies
  • Gene Therapy
  • Physical Therapy and Rehabilitation
  • Supplements and Nutrition
  • Other Treatment Modalities

Healthcare By Mechanism of Action (USD Billion, 2025-2035)

  • Anti-inflammatory Agents
  • Muscle Growth Stimulators
  • Gene Editing Therapies
  • Immunomodulators
  • Other Mechanisms of Action

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Intravenous
  • Intramuscular
  • Transdermal
  • Other Routes of Administration

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓